Healthtech: Europe’s 10 most-funded companies in H1 2026
European healthtech investment in H1 2026 was driven bylarge funding rounds, with continued interest in biotechnology, medical devicesand AI-powered healthcare solutions.The UK attracted significant i...
In the first half of 2026, European healthtech witnessed significant investment, with ten companies raising a combined €2.59 billion. Leading the pack was Isomorphic Labs, an AI-driven drug discovery firm, which secured $2.1 billion in Series B funding. The UK emerged as a major player, attracting substantial investment in companies such as Isomorphic Labs and Oviva.
Isomorphic Labs' IsoDDE platform uses advanced AI models to enhance medicine design and development, targeting cancer and immune disorders. Oviva's digital healthcare programs for managing obesity and chronic conditions, backed by a €200 million Series D round, integrate medical apps with remote support from healthcare professionals.
Alvotech, a biosimilar medicine specialist, raised €100 million in a senior term loan to bolster liquidity and R&D efforts. European healthtech also saw funding for wearable insulin delivery devices, AI-assisted orthodontic care, implantable heart failure devices, and antibody treatments for advanced cancers.
Written by urgent.news from Tech.eu's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
